News Releases

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

Synlogic Adopts Limited Duration Stockholders Rights Plan

Synlogic Announces Decision to Discontinue Synpheny-3 Study and Provides Corporate Update

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Synlogic Provides Corporate Update and Outlook for 2024

Synlogic Announces Contract with the Air Force Research Lab

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

Synlogic Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Synlogic Achieves Research Milestone and Earns $2.5 Million Milestone Payment from Roche Collaboration

Synlogic Announces Closing of $21.0 Million Underwritten Public Offering

Synlogic Announces Pricing of $21.0 Million Underwritten Public Offering

Synlogic Announces Publication of Synpheny-1 Phase 2 Study of Synthetic Biotic for Phenylketonuria in Nature Metabolism

Synlogic Therapeutics